Thrombosis Prediction Based on Reference Ranges of Coagulation-Related Markers in Different Stages of Pregnancy

Introduction: Careful monitoring of the hypercoagulable state is required during pregnancy. However, coagulation and fibrinolysis markers are not fully utilized because there are no reference values reflective of coagulation and fibrinolysis dynamics during pregnancy, which differ from the nonpregnant state. Methods: Changes in antithrombin (AT), fibrinogen (Fbg), prothrombin fragment 1+2 (F1+2), thrombin–antithrombin complex (TAT), soluble fibrin (SF), D-dimer (DD), and protein S (PS) were investigated in healthy pregnant women, and reference ranges in the early, mid, late, and end stages of pregnancy were established. Results: The AT was essentially constant throughout pregnancy. The Fbg, F1+2, TAT, and DD increased significantly as pregnancy progressed. In contrast, SF did not show a significant increase throughout the entire pregnancy period. Total PS antigen and total PS activity showed a corresponding decrease from early gestation. When test data in 3 cases in which deep vein thrombosis or intrauterine fetal death occurred during pregnancy were compared to the established reference ranges, all of the cases had multiple markers with values that exceeded the reference ranges. Conclusion: Establishing reference ranges for each week could potentially make it possible to evaluate abnormalities of the coagulation and fibrinolysis systems during pregnancy. Of note, SF might be a useful marker that reflects thrombus formation during pregnancy. Larger-scale studies will be required to establish reference ranges for every gestational week.

[1]  J. Borg,et al.  Comparison of markers of coagulation activation and thrombin generation test in uncomplicated pregnancies. , 2013, Thrombosis research.

[2]  Rustem I. Litvinov,et al.  Mechanisms of fibrin polymerization and clinical implications. , 2013, Blood.

[3]  F. Klok,et al.  Diagnostic management of acute deep vein thrombosis and pulmonary embolism , 2013, Journal of thrombosis and haemostasis : JTH.

[4]  D. Shi,et al.  Biomarkers of deep venous thrombosis , 2012, Journal of Thrombosis and Thrombolysis.

[5]  N. Hamasaki,et al.  New quantitative total protein S-assay system for diagnosing protein S type II deficiency: clinical application of the screening system for protein S type II deficiency , 2012, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[6]  A. Cooper,et al.  Pre-eclampsia: relationship between coagulation, fibrinolysis and inflammation. , 2011, Clinica chimica acta; international journal of clinical chemistry.

[7]  H. Minakami,et al.  Candidates for the determination of antithrombin activity in pregnant women , 2011, Journal of perinatal medicine.

[8]  S. Diamond,et al.  Thrombin flux and wall shear rate regulate fibrin fiber deposition state during polymerization under flow. , 2010, Biophysical journal.

[9]  T. Wada,et al.  Changes in molecular markers of hemostatic and fibrinolytic activation under various sampling conditions using vacuum tube samples from healthy volunteers. , 2008, Thrombosis research.

[10]  T. Koike,et al.  Soluble fibrin monomer degradation products as a potentially useful marker for hypercoagulable states with accelerated fibrinolysis. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[11]  Takashi Watanabe,et al.  Fibrin monomer complex in normal pregnant women: a potential thrombotic marker in pregnancy , 2007, Annals of clinical biochemistry.

[12]  Hiroyuki Ebinuma,et al.  The monoclonal antibody that recognizes an epitope in the C-terminal region of the fibrinogen alpha-chain reacts with soluble fibrin and fibrin monomer generated by thrombin but not with those formed as plasmin degradation products. , 2007, Thrombosis research.

[13]  J. Kujovich Thrombophilia and pregnancy complications. , 2004, American journal of obstetrics and gynecology.

[14]  S. Koga [A novel molecular marker for thrombus formation and life prognosis--clinical usefulness of measurement of soluble fibrin monomer-fibrinogen complex (SF)]. , 2004, Rinsho byori. The Japanese journal of clinical pathology.

[15]  K. Bremme Haemostatic changes in pregnancy. , 2003, Best practice & research. Clinical haematology.

[16]  H. Wada,et al.  Measurement of soluble fibrin monomer-fibrinogen complex in plasmas derived from patients with various underlying clinical situations. , 2003, Thrombosis and haemostasis.

[17]  Shigenori Suzuki,et al.  Gestational thrombocytopenia and pregnancy-induced antithrombin deficiency: progenitors to the development of the HELLP syndrome and acute fatty liver of pregnancy. , 2002, Seminars in thrombosis and hemostasis.

[18]  Y. Sakata,et al.  A novel monoclonal antibody to fibrin monomer and soluble fibrin for the detection of soluble fibrin in plasma. , 2002, Clinica chimica acta; international journal of clinical chemistry.

[19]  B. Huppertz,et al.  The fibrinoids of the human placenta: origin, composition and functional relevance. , 1996, Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft.

[20]  M. Matsuda,et al.  A monoclonal antibody that recognizes a neo-antigen exposed in the E domain of fibrin monomer complexed with fibrinogen or its derivatives: its application to the measurement of soluble fibrin in plasma. , 1996, Blood.

[21]  Y. Komatsu [Studies on coagulation-fibrinolysis during normal pregnancy, labor and puerperium using recently developed molecular markers]. , 1995, Nihon Sanka Fujinka Gakkai zasshi.

[22]  G. Thurnau,et al.  Functional and immunologic protein S levels are decreased during pregnancy , 1986 .

[23]  E. Brass,et al.  Fibrin Formation: The Role of the Fibrinogen-Fibrin Monomer Complex , 1976, Thrombosis and Haemostasis.